ArticlePharmacoEconomics1999

Choice of cost-effectiveness measure in the economic evaluation of cholesterol-modifying pharmacotherapy. An illustrative example focusing on the primary prevention of coronary heart disease in Canada.

S Morris et al.PubMed ↗Publisher ↗

No numbers read from the abstract.